The purpose of this study is to determine efficacy and safety of the biweekly scheme with Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.~Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~Bevacizumab: 5 mg/kg day 1, every 2 Weeks
The purpose of this study is to determine efficacy and safety of the biweekly scheme with Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.